

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB Endocrinology Paper2
<b>Subject Name :</b>	DrNB Endocrinology Paper2
<b>Creation Date :</b>	2022-06-25 17:20:12
<b>Duration :</b>	180
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DrNB Endocrinology Paper2

<b>Group Number :</b>	1
<b>Group Id :</b>	3271871088
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Break time :</b>	0
<b>Group Marks :</b>	100
<b>Is this Group for Examiner? :</b>	No
<b>Examiner permission :</b>	Cant View
<b>Show Progress Bar? :</b>	No

## DrNB Endocrinology Paper2

<b>Section Id :</b>	3271871091
<b>Section Number :</b>	1

**Section type :** Offline  
**Mandatory or Optional :** Mandatory  
**Number of Questions to be attempted :** 10  
**Section Marks :** 100  
**Enable Mark as Answered Mark for Review and Clear Response :** Yes  
**Maximum Instruction Time :** 0  
**Sub-Section Number :** 1  
**Sub-Section Id :** 3271871095  
**Question Shuffling Allowed :** No

**Question Number : 1 Question Id : 3271879932 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. GLP1 receptor agonists. [10]

**Question Number : 2 Question Id : 3271879933 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Cardiovascular outcome trials in Type 2 diabetes mellitus. [10]

**Question Number : 3 Question Id : 3271879934 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Hyperglycemic emergencies in diabetes mellitus. [10]

**Question Number : 4 Question Id : 3271879935 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Medical management of primary hyperparathyroidism. [10]

**Question Number : 5 Question Id : 3271879936 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Anabolic drug therapy in osteoporosis. [10]

**Question Number : 6 Question Id : 3271879937 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Subacute thyroiditis. [10]

**Question Number : 7 Question Id : 3271879938 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Medical management of Graves' disease in childhood. [10]

**Question Number : 8 Question Id : 3271879939 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Clinical presentation, evaluation and management of primary adrenal deficiency. [10]

**Question Number : 9 Question Id : 3271879940 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Medical management of Cushing's syndrome. [10]

**Question Number : 10 Question Id : 3271879941 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

Tyrosine kinase inhibitors in differentiated thyroid carcinoma. [10]